Mounjaro and cancer
Wang L, Wang W, Kaelber DC, Xu R, Berger NA. GLP-1 Receptor Agonists and Colorectal Cancer Risk in Drug-Naive Patients With Type 2 Diabetes, With and Without Overweight/Obesity. JAMA Oncol. 2024;10(2):256–258. doi:10.1001/jamaoncol.2023.5573
Portillo DU, Mazo-Canola M, Alhaj S. Evaluating the impact of GLP-1 receptor agonists on weight management in patients with breast cancer undergoing endocrine therapy: a comparative analysis. J Clin Oncol. 2024;42(suppl 16):e13063. doi:10.1200/JCO.2024.42.16_suppl.e13063
2
Fischbach NA, Zhou B, Deng Y, Parsons K, Shelton A, Lustberg MB. Impact of semaglutide and tirzepatide administration on weight in women with stage I-III breast cancer. J Clin Oncol. 2024;42(suppl 16):e24140. doi:10.1200/JCO.2024.42.16_suppl.e24140
Shen S, Liu B, Fanti C, et al. Glucagon-like peptide-1 (GLP-1) agonist use and weight change among patients with breast cancer. J Clin Oncol. 2024;42(suppl 16):10607. doi:10.1200/JCO.2024.42.16_suppl.10607